Literature DB >> 10952581

Activities of several antimicrobials against Mycobacterium ulcerans infection in mice.

H Dega1, J Robert, P Bonnafous, V Jarlier, J Grosset.   

Abstract

Mycobacterium ulcerans inoculated into the footpads of mice at 6 x 10(3) CFU was shown to have a generation time of 6.5 days when estimated from weekly changes in microscopic counts of acid-fast bacilli (AFB) and 7.5 days when calculated from actual CFU enumerated on Lowenstein-Jensen egg medium incubated at 32 degrees C. Footpads became swollen at week 10 (W10) after infection, and all infected control mice were dead at W15 after infection. Daily (5 days/week) treatment with 100 mg of clarithromycin (CLR)/kg of body weight beginning the day after infection prevented swelling of footpads at W10. When initiation of treatment was delayed until obvious footpad swelling was observed, there was a reduction in both the increase in AFB counts and deterioration of swollen footpads and also a prolonged survival of the mice to W18. Mice infected in the hind footpads with 5 x 10(5) CFU of M. ulcerans were divided into an untreated control group and six treatment groups that received one of the following therapies for 8 weeks: 100 mg of CLR/kg, 25 mg of minocycline (MIN)/kg, 50 mg of sparfloxacin (SPX)/kg, 10 mg of rifampin (RIF)/kg, 10 mg of rifabutin (RBT)/kg, or 100 mg of amikacin (AMK)/kg. After completion of therapy, treated animals were observed for an additional 17 weeks. All control mice and mice treated with CLR, MIN, or SPX exhibited swollen footpads during the observation period. In contrast, of those animals treated with RIF, RBT, or AMK, none had footpad swelling and all inoculated cultures done after the W17 observation remained negative. These results suggest that RIF, RBT, and AMK may be effective in the treatment of human infection with M. ulcerans.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10952581      PMCID: PMC90071          DOI: 10.1128/AAC.44.9.2367-2372.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Activity of rifampicin on Mycobacterium ulcerans.

Authors:  A Havel; S R Pattyn
Journal:  Ann Soc Belg Med Trop       Date:  1975

2.  [TREATMENT OF EXPERIMENTAL INFECTION BY MYCOBACTERIUM ULCERANS AND MYCOBACTERIUM BALNEI IN MICE].

Authors:  S R PATTYN; J ROYACKERS
Journal:  Ann Soc Belges Med Trop Parasitol Mycol       Date:  1965

3.  A new mycobacterial infection in man.

Authors:  P MacCALLUM; J C TOLHURST
Journal:  J Pathol Bacteriol       Date:  1948-01

4.  Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients.

Authors:  B Ji; P Jamet; E G Perani; S Sow; C Lienhardt; C Petinon; J H Grosset
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

5.  Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model.

Authors:  B Ji; N Lounis; C Truffot-Pernot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

6.  Further study of the effectiveness of single doses of clarithromycin and minocycline against Mycobacterium leprae in mice.

Authors:  J H Xiong; B Ji; E G Perani; C Pétinon; J H Grosset
Journal:  Int J Lepr Other Mycobact Dis       Date:  1994-03

7.  In vitro susceptibility of Mycobacterium ulcerans to clarithromycin.

Authors:  F Portaels; H Traore; K De Ridder; W M Meyers
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

Review 8.  Clarithromycin against Mycobacterium avium complex infections.

Authors:  L B Heifets
Journal:  Tuber Lung Dis       Date:  1996-02

9.  THE EXPERIMENTAL DISEASE THAT FOLLOWS THE INJECTION OF HUMAN LEPROSY BACILLI INTO FOOT-PADS OF MICE.

Authors:  C C Shepard
Journal:  J Exp Med       Date:  1960-09-01       Impact factor: 14.307

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  33 in total

1.  Using bioluminescence to monitor treatment response in real time in mice with Mycobacterium ulcerans infection.

Authors:  Tianyu Zhang; Si-Yang Li; Paul J Converse; Deepak V Almeida; Jacques H Grosset; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

Review 2.  Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?

Authors:  Paul J Converse; Eric L Nuermberger; Deepak V Almeida; Jacques H Grosset
Journal:  Future Microbiol       Date:  2011-10       Impact factor: 3.165

3.  In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.

Authors:  Baohong Ji; Sébastien Lefrançois; Jerome Robert; Aurélie Chauffour; Chantal Truffot; Vincent Jarlier
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

4.  Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans.

Authors:  S Etuaful; B Carbonnelle; J Grosset; S Lucas; C Horsfield; R Phillips; M Evans; D Ofori-Adjei; E Klustse; J Owusu-Boateng; G K Amedofu; P Awuah; E Ampadu; G Amofah; K Asiedu; M Wansbrough-Jones
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

5.  Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection.

Authors:  J W C Alffenaar; W A Nienhuis; F de Velde; A T Zuur; A M A Wessels; D Almeida; J Grosset; O Adjei; D R A Uges; T S van der Werf
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

6.  Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease.

Authors:  Fred Stephen Sarfo; Richard Phillips; Kingsley Asiedu; Edwin Ampadu; Nana Bobi; E Adentwe; Awuli Lartey; Ishmael Tetteh; M Wansbrough-Jones
Journal:  Antimicrob Agents Chemother       Date:  2010-06-21       Impact factor: 5.191

7.  In Vivo Imaging of Bioluminescent Mycobacterium ulcerans: A Tool to Refine the Murine Buruli Ulcer Tail Model.

Authors:  Till F Omansen; Renee A Marcsisin; Brendon Y Chua; Weiguang Zeng; David C Jackson; Jessica L Porter; Ymkje Stienstra; Tjip S van der Werf; Timothy P Stinear
Journal:  Am J Trop Med Hyg       Date:  2019-12       Impact factor: 2.345

8.  In Silico Prediction of Antibiotic Resistance in Mycobacterium ulcerans Agy99 through Whole Genome Sequence Analysis.

Authors:  Sushim Kumar Gupta; Michel Drancourt; Jean-Marc Rolain
Journal:  Am J Trop Med Hyg       Date:  2017-07-27       Impact factor: 2.345

9.  Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice.

Authors:  A Bentoucha; J Robert; H Dega; N Lounis; V Jarlier; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

10.  Telacebec for Ultrashort Treatment of Buruli Ulcer in a Mouse Model.

Authors:  Deepak V Almeida; Paul J Converse; Till F Omansen; Sandeep Tyagi; Rokeya Tasneen; Jeongjun Kim; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.